Standing Order
Kymera Therapeutics, Inc.

Dashboard

Kymera Therapeutics, Inc.

KYMRNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$9.8B
Price$115.3152w $37.68 – $138.86
Conviction3/ 5
Revenue (TTM)$102M
Revenue growth YoY+133.7%
P/E (trailing)—
Gross margin—
Operating margin-396.1%
Net margin-341.9%
52w price change+167.4%
Next earnings—

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 2
    Trial readoutClinicalTrials.gov

    Kymera completes Phase 1 first-in-human study of KT-579 in healthy adults (NCT07412288).

  • Oct 30
    Trial initiationClinicalTrials.gov

    Kymera initiates Phase 1 trial NCT07823205 evaluating different oral formulations of KT-621; status recruiting.

  • Oct 29
    Financial resultsSEC

    Kymera Therapeutics filed 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.

  • Oct 7
    Trial initiationClinicalTrials.gov

    Kymera starts Phase 2 long-term extension study of KT-621 in prior asthma trial participants (NCT07677059, recruiting)

  • Oct 6
    Trial initiationClinicalTrials.gov

    Kymera updates Phase 2 trial NCT07217015 of KT-621 in moderate to severe atopic dermatitis to ACTIVE_NOT_RECRUITING status.

  • Oct 6
    Trial initiationClinicalTrials.gov

    Kymera initiates Phase 2 trial of KT-621 in moderate to severe eosinophilic asthma (NCT07323654, recruiting).

  • Oct 1
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Sep 16
    Trial initiationClinicalTrials.gov

    Phase 1 trial NCT07823205 initiated to evaluate oral formulations of KT-621; recruiting.

  • Sep 4
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Aug 17
    Trial initiationClinicalTrials.gov

    Kymera initiates Phase 2 trial (NCT07323654) of KT-621 in moderate to severe eosinophilic asthma; recruiting status as of 2026-08-17.

  • Aug 5
    Financial resultsSEC

    Kymera Therapeutics files 8-K (items 2.02, 9.01) disclosing financial results.

  • Jul 27
    LeadershipSEC

    8-K filed with items 5.02, 7.01, 9.01 covering officer or director changes and related exhibits.

  • Jul 27
    Ownership changeSEC

    SEC Form 4 filed reporting insider transaction in KYMR shares.

  • Jul 7
    Ownership changeSEC

    Form 4 filing reporting change in beneficial ownership.

  • Jul 2
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Jul 2
    Ownership changeSEC

    SEC Form 4 insider ownership filing.

  • Jul 2
    Ownership changeSEC

    SEC Form 4 insider ownership filing.

  • Jun 30
    Ownership changeSEC

    SEC Form 4 insider transaction filing

  • Jun 30
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Jun 30
    Trial initiationClinicalTrials.gov

    Phase 2 trial (NCT07217015) of KT-621 in moderate to severe atopic dermatitis updated to active, not recruiting.

Not financial advice — research and opinion only. Disclosures